Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
04-Aug-2026 | 622.95 | 655.75 | 621.25 | 644.65 | 41,335 | 92,77,67,335.3 | 6,40,493 |
05-Aug-2026 | 650 | 753.85 | 636.85 | 721.75 | 3,30,779 | 11,85,75,04,536.4 | 21,55,105 |
06-Aug-2026 | 739.1 | 786.15 | 730.3 | 738.8 | 4,00,191 | 15,73,95,02,236.25 | 24,94,959 |
07-Aug-2026 | 740 | 773.75 | 731.45 | 759.75 | 1,31,906 | 4,75,80,87,735 | 7,94,570 |
10-Aug-2026 | 770.3 | 819 | 770.3 | 807.55 | 1,19,312 | 5,07,14,62,406.4 | 17,17,432 |
11-Aug-2026 | 809.45 | 825.4 | 804.25 | 819.7 | 77,043 | 1,97,62,25,103.15 | 8,27,277 |
12-Aug-2026 | 819.5 | 820.95 | 800.1 | 805.2 | 32,377 | 79,33,01,437.5 | 3,99,796 |
13-Aug-2026 | 803.9 | 813 | 769.1 | 807.05 | 51,129 | 1,10,49,70,030.2 | 5,39,946 |
14-Aug-2026 | 811.6 | 825 | 810.05 | 822 | 32,416 | 84,70,38,881.95 | 5,15,990 |
17-Aug-2026 | 822 | 825 | 803.05 | 809.3 | 31,587 | 60,81,64,310.35 | 3,28,796 |
18-Aug-2026 | 808 | 823 | 807.8 | 809.8 | 24,481 | 49,41,77,753.05 | 3,30,051 |
19-Aug-2026 | 810 | 819 | 802.35 | 807.75 | 26,691 | 50,05,53,492.7 | 3,02,713 |
20-Aug-2026 | 814 | 834.1 | 808.35 | 820.95 | 41,755 | 1,07,90,72,353.55 | 5,91,089 |
21-Aug-2026 | 825 | 825 | 810.3 | 814.95 | 26,764 | 58,12,32,923.95 | 3,45,231 |
24-Aug-2026 | 819 | 866.65 | 811.25 | 855.8 | 93,651 | 2,55,19,38,998.8 | 8,83,364 |
25-Aug-2026 | 859 | 869 | 835.5 | 861.55 | 43,486 | 1,02,26,69,972.05 | 3,30,506 |
26-Aug-2026 | 864 | 868.4 | 851.05 | 860.75 | 32,646 | 63,05,75,891.6 | 3,01,130 |
27-Aug-2026 | 860.75 | 919 | 858.65 | 901.85 | 51,129 | 2,00,81,15,846.15 | 10,47,149 |
28-Aug-2026 | 901 | 910 | 890.7 | 903.8 | 33,099 | 79,23,73,817.6 | 3,93,742 |
31-Aug-2026 | 907.15 | 950 | 873.2 | 949.3 | 63,203 | 2,39,60,40,862.5 | 9,82,800 |
01-Sep-2026 | 950 | 952 | 874 | 889.7 | 80,249 | 2,01,32,70,496.4 | 8,47,267 |
02-Sep-2026 | 889 | 930.85 | 887.05 | 928.55 | 48,025 | 1,34,51,23,590.55 | 6,24,530 |
It targets to initiate first-in-human clinical trials in patients with Essential Thrombocythemia and Polycythemia Vera.
Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Lodha Developers, Shilpa Medicare, etc.
USFDA conducted the Good Manufacturing Practices (GMP) inspection from October 24 to October 30 in 2024.
The certification came after a successful inspection by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14, 2025
The partnership will work on a new biological entity (NBE) in the immuno-oncology field to better treat cancer.
Here are some of the stocks that may see significant price movement today: Aditya Birla Real Estate, Shilpa Medicare, Swiggy, etc.
No regulatory issues were raised by the USFDA at Unit-2 during the inspection, the company said in a regulatory filing.
Shilpa Medicare said it has completed Phase 3 trials for SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets in 165 NAFLD patients in India.
The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.
This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
